-
2023-505035-12-00
5
2020-06-12
RET fusion−positive, metastatic Non-Small Cell Lung Cancer
-
2024-513984-22-00
4
2020-03-17
Patients with metastatic GIST
-
2023-509495-42-00
4
2020-02-27
Adult participants with advanced unresectable or metastatic soft-tissu
-
2023-506248-18-00
7
2020-01-07
MET-altered non-small cell lung cancer (NSCLC)
-
2022-502886-71-00
5
2019-11-20
Previously Untreated Locally Advanced Non-small Cell Lung Cancer (LA N
-
2023-504601-36-00
5
2019-11-20
Open-angle Glaucoma
-
2023-507669-24-00
5
2019-11-05
Chronic lymphocytic leukemia
-
2024-514873-22-00
5
2019-10-16
Unresectable locally advanced and/or metastatic soft-tissue sarcoma
-
2024-515308-38-00
5
2019-09-21
Adults patients with isolated acute urticaria presenting to the emerge
-
2022-500785-10-00
5
2019-08-23
Metastatic Castration-Resistant Prostate Cancer
-
2024-513574-21-00
1
2019-08-09
Neoplasms
-
2023-508022-10-00
6
2019-07-25
Rheumatoid Arthritis
-
2022-500413-11-00
5
2019-06-17
Unresected Stage I or II Non-Small Cell Lung Cancer (NSCLC)
-
2023-506829-11-00
5
2019-05-29
Growth Hormone Deficiency in children
-
2023-507777-18-00
4
2019-03-19
Advanced T-Cell Lymphomas (TCL), i.e. Cutaneous T Cell Lymphomas (CTCL
-
2022-502747-35-00
5
2019-02-18
Newly diagnosed advanced (FIGO stage III-IV) high grade epithelial ova
-
2022-502936-38-00
5
2019-01-09
Moderate and Severe Atopic Dermatitis
-
2022-500797-34-00
4
2018-12-17
Treatment of participants with positive cancer for HRRm or HRD.
-
2024-518405-18-00
6
2018-12-07
Depressive disorder
-
2024-515040-23-00
4
2018-11-26
Chronic Myelogenous Leukemia in chronic phase (CML-CP), previously tre
-
2024-514179-17-00
5
2018-10-02
Metastatic (stage IVB), Persistent, or Recurrent Carcinoma of the Cerv
-
2023-509440-97-00
3
2018-09-25
Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (r/r ALL)
-
2023-506543-41-00
5
2018-07-25
Multiple sclerosis (MS)
-
2024-516281-11-00
4
2018-06-06
Acute Myeloid Leukemia (AML)
Myelodysplastic Syndrome (MDS)